Elligo Health Research Announces New CEO
John Potthoff Transitions to Chairman, Barry Simms Promoted to CEOAUSTIN, Texas--(BUSINESS WIRE)--#clinicalresearch--Elligo Health Research®, the largest healthcare-enabling research organization, today...
Pharmaceutical
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Relationship leverages Quest's sequencing and specimen collection expertise with Scipher's precision medicine technologySECAUCUS, NJ and WALTHAM, MA / ACCESSWIRE /...
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by...
Gilead Supports World Health Organization To Bolster Public Health in Bangladesh
NORTHAMPTON, MA / ACCESSWIRE / December 19, 2023 / We're proud to have contributed to this milestone announced by the...
Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease
Proceeds will fund Phase 2 study in thyroid eye disease (TED) with LASN01 and continue development of LASN500 in Investigational...
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) CARDIFF, United Kingdom, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX),...
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
MIAMI, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical...
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
NORSE EIGHT study on track to commence in Q1 2024Resubmission of ONS-5010 Biologics License Application (BLA) in the U.S. expected...
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage...
Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program
SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new...
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
Patent addresses targeted delivery of JAK inhibitors to the gastrointestinal tractSAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics,...
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational...
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,...
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock...
Appointment of Chief Business Officer
19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals...
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
TriMas Life Sciences Expands Its Cleanroom Capabilities
Positions Company for Growth in Medical Technology ApplicationsBLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--TriMas (NASDAQ: TRS) today announced that its Intertech business, part...